This systematic review and meta-analysis examined the impact of preoperative nonopioid medications on postoperative outcomes in patients undergoing arthroscopic surgery. The analysis included 22 studies and focused on opioid consumption standardized to oral morphine equivalents and pain scores measured on a visual analog scale (VAS). The follow-up period was 24 hours. The setting of the studies was not reported. Funding or conflicts of interest were not reported.
Preoperative treatment with any preoperative medication type resulted in a pooled mean reduction of 4.3 mg in postoperative opioid consumption, with a 95% CI of -6.1 to -2.5 and p < .001. When specifically analyzing preoperative COX-2 inhibitor administration, the pooled mean reduction was 4.2 mg, with a 95% CI of -7.9 to -0.5 and p = .03. Preoperative gabapentin administration showed a pooled mean reduction of 6.3 mg, with a 95% CI of -9.6 to -3.0 and p < .001. For VAS pain reduction with COX-2 inhibitors, a statistically significant reduction of 0.3 cm was observed, with a 95% CI of -0.5 to -0.02 and p = .04.
Patients undergoing anterior cruciate ligament reconstruction had higher postoperative opioid consumption compared with those undergoing general knee or shoulder arthroscopies. The heterogeneity of the literature was high, with an I2 of 96% for any preoperative medication, 93% for COX-2 inhibitors, and 90% for gabapentin. Safety data, including adverse events and tolerability, were not reported. The authors note that the current available literature is highly heterogeneous and that observed reductions may not represent clinically meaningful improvements.
View Original Abstract ↓
BACKGROUND: Orthopaedic surgeons frequently overprescribe opioids after arthroscopic surgery. Previous research has shown reductions in postoperative opioid consumption and pain scores with multimodal nonopioid analgesics. However, the clinical effect of preoperative analgesic strategies has not been fully uncovered.
PURPOSE: To assess the outcomes of arthroscopic surgery associated with preoperative treatment with nonopioid medications.
STUDY DESIGN: Systematic review and meta-analysis; Level of evidence, 1.
METHODS: Three online databases (PubMed, MEDLINE, Embase) were searched on December 12, 2024, to identify randomized controlled trials investigating the effect of preoperative intervention on pain management following arthroscopic surgery. Extracted data included patient demographics, surgery type, analgesic protocols (ie, type, dosing, timing), adverse effects, postoperative opioid consumption, and pain scores. Postoperative opioid consumption was standardized and converted to oral morphine equivalents. Pain scores were assessed using the visual analog scale (VAS). Weighted means and meta-analyses were conducted to compare postoperative outcomes. Subgroup analyses were performed by analgesic class (COX-2 inhibitors, gabapentin) and surgery type. The quality of studies was assessed with the Risk of Bias 2 tool.
RESULTS: A total of 22 studies were included in this review. The overall pooled mean reduction in postoperative opioid consumption with any preoperative medication type was 4.3 mg of oral morphine equivalents (95% CI, -6.1 to -2.5; < .001; = 96%) at 24 hours. The pooled mean reduction associated with preoperative COX-2 administration and gabapentin was 4.2 mg (95% CI, -7.9 to -0.5; = .03; = 93%) and 6.3 mg (95% CI, -9.6 to -3.0; < .001; = 90%) at 24 hours, respectively. Preoperative COX-2 inhibitors also yielded a statistically significant VAS pain reduction of 0.3 cm (95% CI, -0.5 to -0.02; = .04). Patients undergoing anterior cruciate ligament reconstruction had higher postoperative opioid consumption as compared with general knee or shoulder arthroscopies.
CONCLUSION: This systematic review demonstrated that preoperative treatment with nonopioid medications, particularly COX-2 inhibitors and gabapentin, is associated with statistically significant reductions in postoperative opioid consumption after arthroscopic surgery. Despite statistically significant findings, observed reductions in postoperative opioid consumption and VAS pain scores may not represent clinically meaningful improvements. The current available literature is highly heterogeneous, indicating the need for high-quality prospective studies to more accurately assess optimal approaches to pain management.